Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: A case report

Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: A case report

Acute disseminated encephalomyelitis (ADEM) is an inflammatory emyelinating disease of the central nervous system that is usually considered a monophasic disease Post-vaccination ADEM has been associated with several vaccines, however, there is scarce information related to SARS-CoV-2 vaccines. We p...

Full description

Saved in:
Bibliographic Details
Published in:Brain, behavior, & immunity. Health Vol. 20; p. 100439
Main Authors: Lazaro, Luciana G., Perea Cossio, Jhon E., Luis, Maria B., Tamagnini, Flavia, Paguay Mejia, Diego A., Solarz, Horacio, Fernandez Liguori, Nora A., Alonso, Ricardo N.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-03-2022
Elsevier
Subjects:
Acute disseminated encephalomyelitis
Corticosteroid therapy
SARS-CoV-2 vaccination
Short Communication
SARS-CoV-2 vaccination
Corticosteroid therapy
Acute disseminated encephalomyelitis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute disseminated encephalomyelitis (ADEM) is an inflammatory emyelinating disease of the central nervous system that is usually considered a monophasic disease Post-vaccination ADEM has been associated with several vaccines, however, there is scarce information related to SARS-CoV-2 vaccines. We present the case of a 26- year-old female who suffered from ADEM four weeks after Gam-COVID-Vac administration. ●Acute disseminated encephalomyelitis is a monophasic acute non-vasculitic inflammatory demyelinating disorder of the central nervous system.●Pathogenesis is suspected to be related to an autoimmune response to myelin triggered by infection or immunisation via molecular mimicry.●Once the SARS-CoV-2 infection was declared a global pandemic, vaccines became one the most important strategies to reduce mortality.●There is current uncertainty about the safety and efficacy of vaccines in all populations of interest.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2666-3546
2666-3546
DOI:10.1016/j.bbih.2022.100439